Table 3.

Clinicopathologic significance of XRCC1 expression in PD-1+ (TILs) and PD1 breast cancers

PD-1 and XRCC1 expression
XRCC1/PD-1XRCC1+/PD-1XRCC1/PD-1+XRCC1+/PD-1+PPadj
(A) Pathologic parameters
Tumor size
 <1 cm4 (6.2%)32 (49.2%)7 (10.8%)22 (33.8%)0.1110.137
 >1–2 cm19 (4.3%)210 (47.9%)41 (9.4%)168 (38.4%)
 >2–5 cm25 (7.1%)129 (36.9%)48 (13.7%)148 (42.3%)
 >5 cm1 (7.7%)4 (30.8%)2 (15.4%)6 (46.2%)
Tumor stage
 126 (5.2%)232 (46.2%)49 (9.8%)195 (38.8%)0.2392.64
 219 (6.6%)118 (40.8%)40 (13.8%)112 (38.8%)
 34 (5.2%)27 (35.1%)8 (10.4%)38 (49.4%)
Tumor grade
 G15 (4.0%)83 (66.9%)6 (4.8%)30 (24.2%)1 × 10−13<0.00001
 G211 (4.1%)152 (56.1%)13 (4.8%)95 (35.1%)
 G333 (7.0%)141 (29.9%)79 (16.7%)219 (46.4%)
NPI
 ≤3.48 (3.6%)139 (62.6%)9 (4.1%)66 (29.7%)2.63 × 10−10<0.00001
 >3.439 (6.4%)224 (37.0%)85 (14%)257 (42.5%)
Mitotic index
 M1 (low; mitoses < 10)7 (2.7%)155 (59.6%)14 (5.4%)84 (32.3%)3.7 × 10−12<0.00001
 M2 (medium; mitoses 10–18)15 (9.1%)76 (46.1%)13 (7.9%)61 (37.0%)
 M3 (high; mitosis >18)27 (6.4%)132 (31.4%)70 (16.7%)191 (45.5)
Tubule formation
 1 (>75% definite tubule)2 (4.7%)30 (69.8%)3 (7.0%)8 (18.6%)0.000001<0.00001
 2 (10%-75% definite tubule)20 (7.4%)139 (51.5%)17 (6.3%)94 (34.8%)
 3 (<10% definite tubule)27 (5.1%)194 (36.5%)77 (14.5%)234 (44%)
Pleomorphism
 1 (Small-regular uniform)1 (8.3%)7 (58.3%)0 (0%)4 (33.3%)1 × 10−13<0.00001
 2 (Moderate variation)15 (4.9%)195 (63.5%)15 (4.9%)82 (26.7%)
 3 (Marked variation)33 (6.3%)160 (30.5%)82 (15.6%)250 (47.6)
Tumor type
 IDC-NST35 (6.4%)200 (36.5%)71 (13.0%)242 (44.2)3.3 × 10−8<0.00001
 Tubular8 (5.2%)93 (60.8%)9 (5.9%)43 (28.1%)
 Medullary1 (4.3%)2 (8.7%)8 (34.8%)12 (52.2%)
 ILC2 (2.6%)49 (62.8%)3 (3.8%)24 (30.8%)
 Others0 (0%)6 (66.7%)1 (11.1%)2 (22.2%)
 Mixed NST & lobular/special type3 (6.5%)19 (41.3%)6 (13.0%)18 (39.1%)
Her2 overexpression
 No40 (5.4%)328 (44.5%)80 (10.9%)289 (39.2)0.1230.1353
 Yes9 (7.1%)42 (33.3%)18 (14.3%)57 (45.2%)
ER status
 Negative18 (7.6%)60 (25.4%)49 (20.8%)109 (46.2)2.87 × 10−12<0.00001
 Positive28 (4.6%)308 (50.1%)46 (7.5%)233 (37.9)
PR
 Negative26 (7.1%)124 (33.8%)67 (18.3%)150 (40.9)8.1 × 10−9<0.00001
 Positive19 (4%)236 (50.2%)31 (6.6%)184 (39.1)